Voyager Therapeutics Inc. (VYGR)
NASDAQ:VYGR
Want to see VYGR full AI Analyst Report?
VYGR Stock Chart & Stats
$4.13
-$0.14(-2.36%)
At close: 4:00 PM EST
$4.13
-$0.14(-2.36%)
Day’s Range― - ―
52-Week Range$2.83 - $5.55
Previous CloseN/A
Volume91.62K
Average Volume (3M)562.88K
Market Cap
$211.47M
Enterprise Value$225.08M
Total Cash (Recent Filing)$141.48M
Total Debt (Recent Filing)$34.57M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Jul 30, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding60,421,288
10 Day Avg. Volume527,770
30 Day Avg. Volume562,885
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.18
Price to Sales (P/S)5.71
P/FCF Ratio-1.71
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue6.17
Enterprise Value/Gross Profit-7.12
Enterprise Value/Ebitda-2.00
Forecast
1Y Price Target
$16.00Price Target Upside287.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.76
Revenue Forecast (FY)$43.53M
Bulls Say, Bears Say
Bulls Say
Pipeline Progress (IND Clearance)Regulatory clearance of the VY1706 IND materially de-risks Voyager’s Alzheimer’s program and creates a clear clinical path. IND clearance enables collection of safety/biomarker data, strengthens partnership and financing prospects, and validates platform capabilities long-term.
Conservative LeverageLow debt relative to equity reduces near-term refinancing and interest burdens for a clinical-stage biotech. Manageable leverage preserves flexibility to raise capital or structure partnerships and lowers bankruptcy risk while the company executes expensive clinical programs.
High Gross MarginsExtremely high gross margins suggest the company’s revenue sources or collaboration economics are high-value and scalable. If operating spend is rebalanced or partnered programs advance, margin structure supports pathway to improved profitability and attractive unit economics over time.
Bears Say
Large Cash Burn / Negative FCFSustained, large negative operating and free cash flow creates significant funding risk for a pre-revenue biotech. Ongoing burn forces dependence on external financing, can delay programs if capital tightens, and materially increases dilution risk absent near-term partnerships or non-dilutive funding.
Profitability Deterioration And Revenue DeclineSharp deterioration in profitability and declining revenue indicate operating expenses have outpaced value capture. This volatile earnings profile undermines internal funding ability, pressures returns, and means the company must demonstrate clinical progress to reverse fundamental weakness.
Equity Erosion And Reliance On External CapitalDoubling authorized shares and prior equity declines reflect a reliance on equity-capital markets to fund operations. While providing optionality, this structural dependence signals potential future dilution and highlights limited retained-capital buffers if clinical milestones are delayed.
Voyager Therapeutics News
VYGR FAQ
What was Voyager Therapeutics Inc.’s price range in the past 12 months?
Voyager Therapeutics Inc. lowest stock price was $2.83 and its highest was $5.55 in the past 12 months.
What is Voyager Therapeutics Inc.’s market cap?
Voyager Therapeutics Inc.’s market cap is $211.47M.
When is Voyager Therapeutics Inc.’s upcoming earnings report date?
Voyager Therapeutics Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were Voyager Therapeutics Inc.’s earnings last quarter?
Voyager Therapeutics Inc. released its earnings results on May 07, 2026. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.081.
Is Voyager Therapeutics Inc. overvalued?
According to Wall Street analysts Voyager Therapeutics Inc.’s price is currently Undervalued.
Does Voyager Therapeutics Inc. pay dividends?
Voyager Therapeutics Inc. does not currently pay dividends.
What is Voyager Therapeutics Inc.’s EPS estimate?
Voyager Therapeutics Inc.’s EPS estimate is -0.51.
How many shares outstanding does Voyager Therapeutics Inc. have?
Voyager Therapeutics Inc. has 60,421,288 shares outstanding.
What happened to Voyager Therapeutics Inc.’s price movement after its last earnings report?
Voyager Therapeutics Inc. reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went up 2.273%.
Which hedge fund is a major shareholder of Voyager Therapeutics Inc.?
Currently, no hedge funds are holding shares in VYGR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (287.41% Upside)
$16.00 (287.41% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 194.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $44.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.77%
12-Months-Change
Fundamentals
Return on Equity
-55.97%
Trailing 12-Months
Asset Growth
-37.91%
Trailing 12-Months
Company Description
Voyager Therapeutics Inc.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
VYGR Stock 12 Month Forecast
Average Price Target
$16.00
▲(287.41% Upside)
Technical Analysis
Galectin Therapeutics
―
Cartesian Therapeutics
―
Silence Therapeutics
―
Tenaya Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
2.21% Insiders
9.71% Mutual Funds
19.12% Other Institutional Investors
59.83% Public Companies and
Individual Investors